Chebrolu Chiranjeevi, Artner Daniel, Sigmund Anna M, Buer Jan, Zamyatina Alla, Kirschning Carsten J
Institute of Medical Microbiology, University of Duisburg-Essen, 45147 Essen, Germany.
Department of Chemistry, University of Natural Resources and Life Sciences, 1190 Vienna, Austria.
Mol Immunol. 2015 Oct;67(2 Pt B):636-41. doi: 10.1016/j.molimm.2015.07.037. Epub 2015 Aug 28.
Immune stimulatory pathogen associated molecular patterns (PAMPs) are major drivers of infection pathology. Infections with Gram-negative bacteria or negatively polar and single stranded RNA influenza virus are prominent causes of morbidity and mortality. Toll-like receptor (TLR) 4 is a major host sensor for both of the two infections. In order to inhibit TLR4 driven immune activation we recently developed synthetic tetra-acylated lipid A mimetics based on a conformationally restricted βGlcN(1↔1)αGlcN disaccharide scaffold (DA-compounds) that antagonized ectopically overexpressed human and murine TLR4/MD-2 complexes. Here we comparatively analyzed human peripheral blood mononuclear cell (hPBMC) and murine bone marrow derived macrophage (mBM) activation upon 30 min of preincubation in vitro with six variably acylated DA-compounds. 16 h subsequent to consequent LPS challenge, we sampled culture supernatants for cytokine and NO concentration analysis. Four compounds significantly inhibited release of both TNF and IL-6 by hPBMCs upon LPS challenge. In contrast, three compounds effectively inhibited mBM production of MIP-2 and KC, and even five of them inhibited IL-6 and NO production. LPS driven like other TLR ligand driven mBM TNF release was largely unimpaired. The inhibitory effect was specific in that Clo75 driven cytokine release by both hPBMCs and mBMs was unimpaired by the compounds analyzed. Our results indicate biological species specificity of LPS antagonism by variably tetraacylated lipid A mimetics and validate three out of six DA-antagonists as promising candidates for development of therapeutically applicable anti-inflammatory compounds.
免疫刺激病原体相关分子模式(PAMPs)是感染病理的主要驱动因素。革兰氏阴性菌感染或负极性单链RNA流感病毒感染是发病和死亡的主要原因。Toll样受体(TLR)4是这两种感染的主要宿主传感器。为了抑制TLR4驱动的免疫激活,我们最近基于构象受限的βGlcN(1↔1)αGlcN二糖支架开发了合成四酰化脂多糖类似物(DA化合物),该化合物可拮抗异位过表达的人和小鼠TLR4/MD-2复合物。在此,我们比较分析了人外周血单核细胞(hPBMC)和小鼠骨髓来源巨噬细胞(mBM)在体外与六种不同酰化的DA化合物预孵育30分钟后的激活情况。在随后的LPS刺激16小时后,我们采集培养上清液进行细胞因子和NO浓度分析。四种化合物在LPS刺激后显著抑制hPBMC释放TNF和IL-6。相比之下,三种化合物有效抑制mBM产生MIP-2和KC,甚至其中五种抑制IL-6和NO的产生。与其他TLR配体驱动的情况一样,LPS驱动的mBM TNF释放基本未受影响。这种抑制作用具有特异性,因为Clo75驱动的hPBMC和mBM细胞因子释放不受所分析化合物的影响。我们的结果表明,不同四酰化脂多糖类似物对LPS的拮抗作用具有生物物种特异性,并验证了六种DA拮抗剂中的三种是开发治疗性抗炎化合物的有前景的候选物。